Study directory

Mental health studies with practical context.

Compare studies and check their requirements with the research team.

Back to overview

10612studies shown

Showing 3,037-3,048 of 10,612

Behavioral study icon

CompletedNCT06486948

An Exploratory, Double-arm, 8-week Study to Explore the Feasibility and Acceptability of Abbreviated Treatment with CT-156 in People with Schizophrenia.

This study is completed in the United States. It focuses on schizophrenia.

In United States

SchizophreniaBehavioralOver 18 Years

Countries: United States
Sponsor: Click Therapeutics, Inc.
Condition: Schizophrenia

Behavioral study icon

CompletedNCT05172609

An Exposure-Based Implementation Strategy to Decrease Clinician Anxiety Around Suicide prevention

This summary needs review. Please check the official study record and contact the research team for details.

In United States

Suicidality, AnxietyBehavioralOver 18 Years

Countries: United States
Sponsor: University of Pennsylvania
Condition: Suicidality, Anxiety

Behavioral study icon

CompletedNCT03553992

An Extended Facebook Intervention for Young Sexual and Gender Minority Smokers

This summary needs review. Please check the official study record and contact the research team for details.

In United States

AddictionBehavioralFrom 18 Years to 25 Years

Countries: United States
Sponsor: University of California, San Francisco
Condition: Addiction

Drug study icon

CompletedNCT01895452

An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)

This summary needs review. Please check the official study record and contact the research team for details.

In United States

SchizophreniaDrugFrom 18 Years to 70 Years

Countries: United States, Bulgaria, Malaysia, ...
Sponsor: Alkermes, Inc.
Condition: Schizophrenia

Device study icon

TerminatedNCT05526833

An Extension Protocol for Patients Who Previously Completed the TMS Study

This summary needs review. Please check the official study record and contact the research team for details.

In United States

SchizophreniaDeviceFrom 22 Years to 55 Years

Countries: United States
Sponsor: Columbia University
Condition: Schizophrenia

Behavioral study icon

CompletedNCT06067984

Second Course of a Digital Therapeutic for schizophrenia

This study is completed in the United States. It is testing second Course of a Digital Therapeutic for schizophrenia.

In United States

SchizophreniaBehavioralOver 18 Years

Countries: United States
Sponsor: Click Therapeutics, Inc.
Condition: Schizophrenia

Drug study icon

CompletedNCT02970929

An Extension Study of Safety and Tolerability of SEP-363856 in Adult Subjects With Schizophrenia

This summary needs review. Please check the official study record and contact the research team for details.

In United States

SchizophreniaDrugFrom 18 Years to 40 Years

Countries: United States, Hungary, Romania, ...
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition: Schizophrenia

Drug study icon

CompletedNCT05741528

An Extension Study to a Clinical Study That Will Continue Effectiveness and Safety of SEP-363856 in People With Schizophrenia That Switch to SEP-363856 From Their From Their Current Antipsychotic Medication

This study is completed in the United States. It focuses on schizophrenia.

In United States

SchizophreniaDrugFrom 18 Years to 65 Years

Countries: United States
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition: Schizophrenia

Drug study icon

CompletedNCT05304767

Safety study of KarXT in schizophrenia

This study is completed in the United States, in Bulgaria, in Japan, .... It is testing KarXT for schizophrenia.

In United States

SchizophreniaDrugFrom 18 Years to 65 Years

Countries: United States, Bulgaria, Japan, ...
Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Condition: Schizophrenia

Drug study icon

CompletedNCT04659174

Safety study of Long-term Safety, Tolerability, and Efficacy of KarXT in schizophrenia

This study is completed in the United States and in Ukraine. It is testing Long-term Safety, Tolerability, and Efficacy of KarXT for schizophrenia.

In United States

SchizophreniaDrugFrom 18 Years to 65 Years

Countries: United States, Ukraine
Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Condition: Schizophrenia

Behavioral study icon

CompletedNCT00345943

An fMRI Study of Self-regulation in Adolescents With Eating disorders

This summary needs review. Please check the official study record and contact the research team for details.

In United States

Eating disordersBehavioralFrom 12 Years to 17 Years

Countries: United States
Sponsor: New York State Psychiatric Institute
Condition: Eating disorders

Drug study icon

TerminatedNCT02259517

An fMRI Study of Stimulant vs. Non-Stimulant Treatment of ADHD

This summary needs review. Please check the official study record and contact the research team for details.

In United States

ADHDDrugFrom 6 Years to 17 Years

Countries: United States
Sponsor: New York State Psychiatric Institute
Condition: ADHD

Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.